Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis

Summary

GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A nationwide multi-centred randomised controlled trial (RCT) investigating the use of GLM dose adjustment in ulcerative colitis (UC). The primary objective is to ascertain if dose adjustment of GLM based on GLM drug levels and FCP levels results in higher response and remission rates than standard SmPC dosing.

Timeline

Start

2016-06

Primary completion

2020-02

Completion

2020-02

Drugs

Indications